cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2025-4361FQMMNWcardiovascular-4361Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMD-димер как фактор риска развития сердечно-сосудистых осложнений у пациентов с заболеваниями печениD-dimer as a risk factor for cardiovascular events in patients with liver diseaseshttps://orcid.org/0000-0001-9351-6177РубаненкоО. А.RubanenkoO. A.

Рубаненко Олеся Анатольевна — д.м.н., доцент кафедры госпитальной терапии с курсами гематологии и трансфузиологии

Самара

Samara

olesya.rubanenko@gmail.comhttps://orcid.org/0000-0002-0555-4016ЗолотовскаяИ. А.ZolotovskayaI. A.

Д..м.н., профессор кафедры госпитальной терапии с курсами гематологии и трансфузиологии

Самара

Samara

https://orcid.org/0000-0001-5183-1208ШацкаяП. Р.ShatskayaP. R.

Аспирант кафедры пропедевтической терапии с курсом кардиологии, врач-кардиолог ГБУЗ «Самарский областной клинический кардиологический диспансер» им. В.П. Полякова

Самара

Samara

ФГБОУ ВО "Самарский государственный медицинский университет" Минздрава РоссииSamara State Medical UniversityФГБОУ ВО "Самарский государственный медицинский университет" Минздрава России; ГБУЗ "Самарский областной клинический кардиологический диспансер им. В. П. Полякова"Samara State Medical University; Polyakov Samara Regional Clinical Cardiology Dispensary20252004202524343614361Copyright © Рубаненко О.А., Золотовская И.А., Шацкая П.Р., 20252025Рубаненко О.А., Золотовская И.А., Шацкая П.Р.Rubanenko O.A., Zolotovskaya I.A., Shatskaya P.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/4361

Взаимосвязь между сердечно-сосудистыми заболеваниями и патологией печени представляет собой значимую клиническую проблему; поскольку заболевания одной системы могут усугублять состояние другой. Одним из ключевых маркеров для оценки риска сердечно-сосудистых осложнений у пациентов с заболеваниями печени является D-димер — продукт фибринолиза; уровень которого повышается при активации свертывающей системы. Важно отметить роль адеметионина (Гептрал®) в поддержке функции печени; снижении воспаления и окислительного стресса; что может снижать развитие и прогрессирование атеросклеротического процесса и сердечно-сосудистых осложнений у пациентов с печеночной патологией. Определение D-димера важно при стратификации риска и оценке клинических исходов у пациентов с печеночной и сердечнососудистой коморбидностью; в т.ч. на фоне терапии адеметионином. 

The relationship between cardiovascular and liver diseases is a significant clinical problem; since diseases of one system can aggravate the other. One of the key markers for cardiovascular risk assessment in patients with liver diseases is D-dimer. This is a fibrin degradation product; the level of which increases with the coagulation system activation. It is important to note the role of ademetionine (Heptral®) in supporting liver function; reducing inflammation and oxidative stress; which can reduce the development and progression of atherosclerosis and cardiovascular complications in patients with liver disease. Determination of D-dimer is important in risk stratification and assessment of clinical outcomes in patients with liver and cardiovascular comorbidity; including those treated with ademetionine.

заболевания печенисердечно-сосудистые осложненияD-димерадеметионинliver diseasecardiovascular eventsD-dimerademetionineReferencesIglesias Morcillo M, Freuer D, Peters A, et al. Association between fatty liver index and blood coagulation markers: a population-based study. Lipids Health Dis. 2023;22(1):83. doi:10.1186/s12944-023-01854-8.Iglesias Morcillo M, Freuer D, Peters A, et al. Association between fatty liver index and blood coagulation markers: a population-based study. Lipids Health Dis. 2023;22(1):83. doi:10.1186/s12944-023-01854-8.Hörber S, Lehmann R, Stefan N, et al. Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Mol Metab. 2021;53:101262. doi:10.1016/j.molmet.2021.101262.Hörber S, Lehmann R, Stefan N, et al. Hemostatic alterations linked to body fat distribution, fatty liver, and insulin resistance. Mol Metab. 2021;53:101262. doi:10.1016/j.molmet.2021.101262.Virović-Jukić L, Stojsavljević-Shapeski S, Forgač J, et al. Non-alcoholic fatty liver disease — a procoagulant condition? Croat Med J. 2021;62(1):25-33. doi:10.3325/cmj.2021.62.25.Virović-Jukić L, Stojsavljević-¬Shapeski S, Forgač J, et al. Non-alcoholic fatty liver disease — a procoagulant condition? Croat Med J. 2021;62(1):25-33. doi:10.3325/cmj.2021.62.25.Berardo C, Di Pasqua LG, Cagna M, et al. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci. 2020;21(24):9646. doi:10.3390/ijms21249646.Berardo C, Di Pasqua LG, Cagna M, et al. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci. 2020;21(24):9646. doi:10.3390/ijms21249646.Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi:10.1016/j.jhep.2020.03.039.Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-9. doi:10.1016/j.jhep.2020.03.039.Geier A, Tiniakos D, Denk H, et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut. 2021;70(8):1570-9. doi:10.1136/gutjnl-2020-323202.Geier A, Tiniakos D, Denk H, et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut. 2021;70(8):1570-9. doi:10.1136/gutjnl-2020-323202.Ogresta D, Mrzljak A, Cigrovski Berkovic M, et al. Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. J Clin Transl Hepatol. 2022;10(2):339-55. doi:10.14218/JCTH.2021.00268.Ogresta D, Mrzljak A, Cigrovski Berkovic M, et al. Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. J Clin Transl Hepatol. 2022;10(2):339-55. doi:10.14218/JCTH.2021.00268.Li Y, Qi X, Li H, et al. D-dimer level for predicting the in-hospital mortality in liver cirrhosis: a retrospective study. Exp Ther Med. 2017;13(1):285-9. doi:10.3892/etm.2016.3930.Li Y, Qi X, Li H, et al. D-dimer level for predicting the in-hospital mortality in liver cirrhosis: a retrospective study. Exp Ther Med. 2017;13(1):285-9. doi:10.3892/etm.2016.3930.Zou B, Yeo YH, Cheung R, et al. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Dig Dis Sci. 2021;66(6):2092-100. doi:10.1007/s10620-021-06954-y.Zou B, Yeo YH, Cheung R, et al. Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. Dig Dis Sci. 2021;66(6):2092-100. doi:10.1007/s10620-021-06954-y.Kim JH, Moon JS, Byun SJ, et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovasc Diabetol. 2020;19(1):51. doi:10.1186/s12933-020-01025-4.Kim JH, Moon JS, Byun SJ, et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-¬based study. Cardiovasc Diabetol. 2020;19(1):51. doi:10.1186/s12933-020-01025-4.Sharma D, Gotlieb N, Farkouh ME, et al. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. J Am Heart Assoc. 2022;11(1):e022576. doi:10.1161/JAHA.121.022576.Sharma D, Gotlieb N, Farkouh ME, et al. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort. J Am Heart Assoc. 2022;11(1):e022576. doi:10.1161/JAHA.121.022576.Tripodi A. Hemostasis in acute and chronic liver disease. Semin Liver Dis. 2017;37(1):28-32.Tripodi A. Hemostasis in acute and chronic liver disease. Semin Liver Dis. 2017;37(1):28-32.van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci. 2020;21(9):3294. doi:10.3390/ijms21093294.van Dievoet MA, Eeckhoudt S, Stephenne X. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade? Int J Mol Sci. 2020;21(9):3294. doi:10.3390/ijms21093294.Stotts MJ, Lisman T, Intagliata NM. The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis. Semin Thromb Hemost. 2020;46(6):716-23. doi:10.1055/s-0040-1715449.Stotts MJ, Lisman T, Intagliata NM. The Spectrum of Disea¬se Severity in Cirrhosis and Its Implications for Hemostasis. Semin Thromb Hemost. 2020;46(6):716-23. doi:10.1055/s-0040-1715449.Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. doi:10.1016/j.cpcardiol.2023.101643.Bisaccia G, Ricci F, Khanji MY, et al. Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2023;48(6):101643. doi:10.1016/j.cpcardiol.2023.101643.Huang D, Refaat M, Mohammedi K, et al. Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017;2017:7839101. doi:10.1155/2017/7839101.Huang D, Refaat M, Mohammedi K, et al. Macrovascular Complications in Patients with Diabetes and Prediabetes. Biomed Res Int. 2017;2017:7839101. doi:10.1155/2017/7839101.Yang ZJ, Costa KA, Novelli EM, et al. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost. 2014;20(2):169-78. doi:10.1177/1076029612461846.Yang ZJ, Costa KA, Novelli EM, et al. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost. 2014;20(2):169-78. doi:10.1177/1076029612461846.O’Leary JG, Greenberg CS, et al. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019;157(1):34-43.e1. doi:10.1053/j.gastro.2019.03.070.O’Leary JG, Greenberg CS, et al. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019;157(1):34-43.e1. doi:10.1053/j.gastro.2019.03.070.Енисеева Е. С. Антикоагулянтная терапия у больных с циррозом печени (обзор литературы). Acta Biomed Sci. 2019;4(2):23-8. doi:10.29413/ABS.2019-4.2.3.Eniseeva ES. Anticoagulation in Patients with Liver Cirrhosis (Literature Review). Acta Biomedica Scientifica. 2019;4(2):23-8. (In Russ.) doi:10.29413/ABS.2019-4.2.3.Ивашкин В. Т., Маевская М. В., Жаркова М. С. и др. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(6):56-102. doi:10.22416/1382-4376-2021-31-6-56-102.Ivashkin VT, Maevskaya MV, Zharkova MS, et al. Clinical Recommendations of the Russian Scientific Liver Society and Rus¬sian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):56-102. (In Russ.) doi:10.22416/1382-4376-2021-31-6-56-102.Канорский С. Г. Неалкогольная жировая болезнь печени: современные подходы к диагностике и лечению. Южно-Российский журнал терапевтической практики. 2021;2(3):18-29. doi:10.21886/2712-8156-2021-2-3-18-29.Kanorskii SG. Non-alcoholic fatty liver disease: modern ap¬proaches to diagnosis and treatment. South Russian Jour¬nal of Therapeutic Practice. 2021;2(3):18-29. (In Russ.) doi:10.21886/2712-8156-2021-2-3-18-29.Kremers B, Wübbeke L, Mees B, et al. Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2020;40(9):2018-32. doi:10.1161/ATVBAHA.120.314774.Kremers B, Wübbeke L, Mees B, et al. Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2020;40(9):2018-32. doi:10.1161/ATVBAHA.120.314774.Kleinegris MC, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. A systematic review. Thromb Haemost. 2013;110(2):233-43. doi:10.1160/TH13-01-0032.Kleinegris MC, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. A systematic review. Thromb Haemost. 2013;110(2):233-43. doi:10.1160/TH13-01-0032.Qi T, Zhu C, Lu G, et al. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study. BMC Gastroenterol. 2019;19(1):20. doi:10.1186/s12876-019-0941-0.Qi T, Zhu C, Lu G, et al. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study. BMC Gastroenterol. 2019;19(1):20. doi:10.1186/s12876-019-0941-0.Zhou T, Sun X, Zhou T, et al. Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. Clin Transl Gastroenterol. 2020;11(9):e00228. doi:10.14309/ctg.0000000000000228.Zhou T, Sun X, Zhou T, et al. Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. Clin Transl Gastroenterol. 2020;11(9):e00228. doi:10.14309/ctg.0000000000000228.Pan J, Wang L, Gao F, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med. 2022;104:21-32. doi:10.1016/j.ejim.2022.05.032.Pan J, Wang L, Gao F, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. Eur J Intern Med. 2022;104:21-32. doi:10.1016/j.ejim.2022.05.032.Lin GS, Xu Q, Zhao SY, et al. Clinical features of liver cirrhosis complicated by portal vein thrombosis and related risk factors. Zhonghua Gan Zang Bing Za Zhi. 2016;24(7):513-7. Chinese. doi:10.3760/cma.j.issn.1007-3418.2016.07.006.Lin GS, Xu Q, Zhao SY, et al. Clinical features of liver cirrhosis complicated by portal vein thrombosis and related risk factors. Zhonghua Gan Zang Bing Za Zhi. 2016;24(7):513-7. Chinese. doi:10.3760/cma.j.issn.1007-3418.2016.07.006.Song Z, Uriarte S, Sahoo R, et al. S-adenosylmethionine (SAMe) modulates interleukin-10 and interleukin-6, but not TNF, production via the adenosine (A2) receptor. Biochim Biophys Acta. 2005;1743(3):205-13. doi:10.1016/j.bbamcr.2004.12.001.Song Z, Uriarte S, Sahoo R, et al. S-adenosylmethionine (SAMe) modulates interleukin-10 and interleukin-6, but not TNF, production via the adenosine (A2) receptor. Biochim Biophys Acta. 2005;1743(3):205-13. doi:10.1016/j.bbamcr.2004.12.001.Vergani L, Baldini F, Khalil M, et al. New Perspectives of S-Adeno-sylmethionine (SAMe) Applications to Attenuate Fatty Acid-Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells. Molecules. 2020;25(18):4237. doi:10.3390/molecules25184237.Vergani L, Baldini F, Khalil M, et al. New Perspectives of S-Adeno-sylmethionine (SAMe) Applications to Attenuate Fatty Acid-¬Induced Steatosis and Oxidative Stress in Hepatic and Endothelial Cells. Molecules. 2020;25(18):4237. doi:10.3390/molecules25184237.Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi:10.1016/j.jhep.2012.04.041.Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi:10.1016/j.jhep.2012.04.041.Ивашкин В. Т., Барановский А. Ю., Райхельсон К. Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019; 29(1):85-115. doi:10.22416/1382-4376-2019-29-1-101-131.Ivashkin VT, Baranovsky AYu, Raikhelson KL, et al. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85-115. (In Russ.) doi:10.22416/1382-4376-2019-29-1-101-131.Райхельсон К. Л., Буеверов А. О., Кондрашина Э. А. и др. Внутрипеченочный холестаз при хронических заболеваниях печени и роль адеметионина в его лечении (обзор литературы и резолюция Совета экспертов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(4):20-33. doi:10.22416/1382-4376-2024-1167-3098-1.Raikhelson KL, Bueverov AO, Kondrashina EA, et al. Cholestasis in Chronic Liver Disease and the Role of Ademetionine in its Treatment (Literature Review and Expert Panel Resolution). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(4):20-33. (In Russ.) doi:10.22416/1382-4376-2024-1167-3098-1.

The authors declare that there are no conflicts of interest present.